| Literature DB >> 28399865 |
Xiugong Gao1, Vanessa D Topping2, Zachary Keltner2, Robert L Sprando2, Jeffrey J Yourick2.
Abstract
BACKGROUND: The widespread application of silver nanoparticles (AgNPs) and silver-containing products has raised public safety concerns about their adverse effects on human health and the environment. To date, in vitro toxic effects of AgNPs and ionic silver (Ag+) on many somatic cell types are well established. However, no studies have been conducted hitherto to evaluate their effect on cellular transcriptome in embryonic stem cells (ESCs).Entities:
Keywords: Developmental toxicity; Embryonic stem cell; Silver ion; Silver nanoparticles; Transcriptomics
Mesh:
Substances:
Year: 2017 PMID: 28399865 PMCID: PMC5387260 DOI: 10.1186/s12951-017-0265-6
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Physicochemical properties of silver nanoparticles
| Dispersant | Concentration (mg/ml) | TEM diameter (nm) | DLS diameter (nm) | PDI | ζ-potential (mV) |
|---|---|---|---|---|---|
| 2 mM citratea | 1.06 | 20.6 ± 3.6 | 26.2 | – | −39.8 |
| Water | 1.01 | 20.4 ± 3.2 | 29.3 | 0.048 | – |
| Mediumb | – | 20.2 ± 4.1 | 78.6 | 0.349 | – |
TEM transmission electron microscopy, DLS dynamic light scattering; PDI polydispersity index
aValues provided by the manufacturer for the lot used in the current study
bESGRO Complete Basal Medium (EMD Millipore) used for EB formation and exposure
– Data not available
Fig. 1Characterization of AgNPs. a Typical TEM images of AgNPs in water. b Typical TEM images of AgNPs in cell culture medium. The size bar at the bottom left corner of the images represents 20 nm. c Comparison of hydrodynamic size distribution of AgNPs in water and in cell culture medium. d Monitoring of AgNP stability by UV–vis spectra over 24 h incubation in cell culture medium
Fig. 2Dose response of AgNP and Ag+ exposure. Differentiating mESCs in adherent culture (a) or in EB state (b) were exposed to different concentrations of AgNPs and Ag+ for 24 h, and cell viability was measured by MTS assay. The data were normalized to the control (100%) and expressed as mean ± SD. *p < 0.05
Fig. 3Global gene expression responses of AgNPs and Ag+ in differentiating mESCs. a Schematic representation of the experimental procedure. The slate blue arrow covers the embryoid body (EB) formation stage. Hanging drops were set up on day 0 and EBs formed on day 3. ESC differentiation started from day 3 onwards. AgNP or Ag+ exposure is shown by the maroon arrow, which lasted for 24 h (from day 3 to day 4). b Principal component analysis (PCA) using 16,510 filtered genes to cluster samples based on their similarities or dissimilarities. The three axes represent the first three principal components identified by the analysis. c Hierarchical cluster analysis using 459 unique DEGs to cluster samples based on their similarities or dissimilarities. The clustering was performed through Ward’s minimum variance linkage on normalized expression data which are in log2 scale and color coded as shown in the scheme at the top right corner. The tree on the right of the image shows clusters of genes (names not shown), while the tree on the top of the image shows clusters of samples. Samples labeled as Ag+ were treated with 5.0 µg/ml of Ag+. Those treated with 1.0 µg/ml Ag+ were omitted from the analysis
Number of differentially expressed genes (|FC| ≥ 1.5, p < 0.05)
| All | Upregulated | Downregulated | |
|---|---|---|---|
| AgNP vs Ctrl | 101 (17)a | 43 (6) | 58 (11) |
| Ag+ vs Ctrl | 400 (133) | 137 (41) | 263 (92) |
| AgNP vs Ag+ | 173 (39) | 116 (32) | 57 (7) |
aValues in the parentheses indicate the number of genes that had |FC| ≥ 2.0
Fig. 4Venn Diagrams of upregulated, downregulated or all DEGS after exposure to AgNPs or Ag+ in comparison to the control, or compared with each other
Fig. 5Distribution of enriched GO terms in various functional classes for the DEGs regulated by AgNPs or Ag+. The vertical axis lists all the classes generated by GO slim. The horizontal axis indicates the number of GO terms in each class as a percentage of the total number of unique GO terms enriched by the DEGs
List of pathways impacted by AgNPs or Ag+ and DEGs involved in the pathways
| Ingenuity Canonical Pathways | AgNPs | Ag+ | ||
|---|---|---|---|---|
| p value | Molecules | p value | Molecules | |
| Embryonic development | ||||
| Transcriptional regulatory network in embryonic stem cells | 0.0005 | HAND1, L1CAM, FOXC1 | 0.0000 | HAND1, GATA6, L1CAM, EOMES, SKIL, HOXB1, FOXC1, GATA4 |
| Human embryonic stem cell pluripotency | 0.0178 | SMAD7, SMAD6, BMP5 | 0.0074 | BMP4, WNT3, BMP2, SMAD7, SMAD6, BMP5, FZD2 |
| Mouse embryonic stem cell pluripotency | 0.0002 | LIFR, MYC, ID1, ID2, BMP4, T, ID3, FZD2 | ||
| Role of NANOG in mammalian embryonic stem cell pluripotency | 0.0001 | LIFR, BMP4, T, WNT3, BMP2, GATA6, BMP5, FZD2, GATA4 | ||
| Embryonic stem cell differentiation into cardiac lineages | 0.0115 | T, GATA4 | ||
| Factors promoting cardiogenesis in vertebrates | 0.0045 | BMP4, WNT3, BMP2, BMP5, FZD2, GATA4 | ||
| Cardiomyocyte differentiation via BMP receptors | 0.0022 | SMAD6, BMP5 | 0.0000 | BMP4, BMP2, SMAD6, BMP5, GATA4 |
| Regulation of the epithelial–mesenchymal transition pathway | 0.0407 | FOXC2, FGF14, PARD6B | 0.0003 | ETS1, FOXC2, ID2, FGF10, WNT3, FGF14, PARD6B, FGF3, NOTCH1, FZD2, FGF19 |
| Hepatic fibrosis/hepatic stellate cell activation | 0.0010 | IGFBP4, COL4A1, FLT1, KLF6, SMAD7, LAMA1, BAMBI, IGFBP5, COL4A2, KDR | ||
| Axonal guidance signaling | 0.0000 | SLIT3, SHH, PAPPA, BMP4, WNT3, BMP2, UNC5B, L1CAM, HHIP, SLIT2, ROBO3, BMP5, NTN1, EFNB2, PRKAR2B, GLIS1, TUBB4A, FZD2, PTCH2, NRP1, UNC5C | ||
| BMP signaling pathway | 0.0034 | SMAD7, SMAD6, BMP5 | 0.0003 | BMP4, PRKAR2B, BMP2, SMAD7, SMAD6, BMP5, CHRD |
| ERK5 signaling | 0.0209 | MYC, RPS6KA6, SGK1, CREB3L4 | ||
| FGF signaling | 0.0141 | FGF10, FGF14, CREB3L4, FGF3, FGF19 | ||
| Netrin signaling | 0.0040 | PRKAR2B, UNC5B, NTN1, UNC5C | ||
| Notch signaling | 0.0004 | DLL1, LFNG, DLL3, HES7, NOTCH1 | ||
| RAR activation | 0.0427 | ALDH1A2, SMAD7, SMAD6 | 0.0148 | PRKAR2B, CYP26A1, BMP2, ALDH1A2, SMAD7, SMAD6, ADCY8, RBP1 |
| Sonic Hedgehog signaling | 0.0001 | SHH, PRKAR2B, GLIS1, HHIP, PTCH2 | ||
| TGF-β signaling | 0.0490 | SMAD7, SMAD6 | ||
| eNOS signaling | 0.0191 | Hspa1b, HSPA1A/HSPA1B, KDR | 0.0007 | PRKAR2B, FLT1, HSPA1A/HSPA1B, PRKAA2, AQP8, ADCY8, KDR, LPAR3, NOSTRIN |
| VEGF family ligand-receptor interactions | 0.0389 | KDR, NRP1 | ||
| Metabolism | ||||
| Choline biosynthesis III | 0.0490 | HMOX1 | ||
| Corticotropin releasing hormone signaling | 0.0389 | SHH, PRKAR2B, CREB3L4, ADCY8, PTCH2 | ||
| FXR/RXR activation | 0.0200 | TTR, APOB, VTN, VLDLR, MTTP, FGF19 | ||
| Heme degradation | 0.0166 | HMOX1 | ||
| Histamine degradation | 0.0490 | ALDH1A2 | ||
| NAD biosynthesis II (from tryptophan) | 0.0490 | TDO2 | ||
| Retinoate biosynthesis I | 0.0174 | BMP2, ALDH1A2, RBP1 | ||
| Serotonin degradation | 0.0145 | UGT2B28, ALDH1A2 | ||
| Sulfate activation for sulfonation | 0.0331 | PAPSS2 | ||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | 0.0288 | TDO2 | ||
| Tyrosine biosynthesis IV | 0.0490 | PCBD1 | ||
| Vitamin-C transport | 0.0251 | SLC23A1, GLRX | ||
| Xenobiotic metabolism signaling | 0.0178 | UGT2B28, HMOX1, ALDH1A2, CES2 | ||
| Stress response | ||||
| Unfolded protein response | 0.0209 | Hspa1b, HSPA1A/HSPA1B | ||
| Cancer | ||||
| Molecular mechanisms of cancer | 0.0013 | SHH, Naip1 (includes others), BMP4, WNT3, BMP2, SMAD7, SMAD6, BMP5, MYC, CCND2, PRKAR2B, ADCY8, FZD2, NOTCH1, PTCH2 | ||
| Basal cell carcinoma signaling | 0.0000 | SHH, BMP4, WNT3, GLIS1, BMP2, HHIP, BMP5, FZD2, PTCH2 | ||
| Bladder cancer signaling | 0.0155 | MYC, FGF10, FGF14, FGF3, FGF19 | ||
Fig. 6Pathway interaction networks for DEGs affected by a AgNPs and b Ag+. Each rectangular box represents a pathway affected by the DEGs with the name indicated. The darkness of the red color of each box represents the p value for enrichment of each pathway—the darker the color, the lower the p value. A line linking two boxes represents an interaction between two pathways. The length of the line is arbitrary
Fig. 7Upregulation of several members of the heat shock protein and the metallothionein families by AgNPs, but not Ag+. a Heat map showing the normalized expression intensity in the different treatment groups, which are in log2 scale and color coded as shown in the scheme at the top right corner. b Bar graph showing fold change (FC) of each member of the heat shock protein and the metallothionein families after exposure to AgNPs or to Ag+. The FC values are relative to the controls (of which the mean value was set to 1)
Fig. 8Flow cytometry results showing the effect of AgNPs and Ag+ on oxidative stress and apoptosis in mESCs. a Representative dot plots showing intensities of yellow fluorescence from MitoSox Red staining (oxidative stress) vs. red2 fluorescence from Annexin V binding (apoptosis) in control cells (Ctrl), and cells treated with Ag+ or AgNPs. b Representative histogram graphs showing fluorescence intensity distribution of yellow fluorescence from MitoSox Red staining (oxidative stress, left) and red2 fluorescence from Annexin V binding (apoptosis, right) in control cells (Ctrl), and cells treated with Ag+ or AgNPs. c Bar graphs showing the percentage of cells positive for MitoSox Red staining and Annexin V binding (gated cells in R3 and R4 of B, respectively; left), and mean relative fluorescence intensity (RFI; right) in total cell population of control cells (Ctrl), and cells treated with Ag+, AgNPs, or 1 µM staurosporine (STS). Values are expressed as percentage of the control and are mean ± SD of three independent experiments. *p < 0.05
Fig. 9Schematic representation of molecular mechanisms of AgNP toxicity in ESCs, which are similar to those previously reported for somatic cells. AgNPs enter ESCs via endocytosis, release Ag+ within the cell after lysosome rupture, and subsequently generate ROS. The elevated ROS may lead to DNA damage and cause the cell into cycle arrest in order to repair damaged DNA. Cells failed to do so will eventually undergo apoptosis